Astec LifeSciences: Should You Buy, Hold, or Sell Right Now?
- September 8, 2026
- Posted by: Lakshit Sharma
- Category: Market
Astec LifeSciences share price Rs 570.85 (NSE), up over 3% today, well off its 52-week high. 52-week range Rs 512.35 to Rs 941.75. Losses narrowing across recent quarters.
Quick Answer
Astec LifeSciences Ltd share price is trading around Rs 571, up more than 3 percent today, more than 39 percent below its 52-week high of Rs 941.75 but above its 52-week low of Rs 512.35. Q1 FY27 revenue fell 8 percent year on year to Rs 84.29 crore, with a net loss of Rs 18.71 crore, wider than the loss of Rs 15.69 crore in the December 2025 quarter but narrower than earlier quarters, including a Rs 33.03 crore loss a year ago. Full-year FY25 revenue grew 17.1 percent, with the annual net loss narrowing to Rs 80.88 crore from Rs 134.71 crore in FY24. This is a truly distressed agrochemical intermediates manufacturer showing a gradual improvement that has not yet reached profitability.
Astec LifeSciences share price is up more than 3 percent today, trading around Rs 571 on the NSE, more than 39 percent below its 52-week high of Rs 941.75, above its 52-week low of Rs 512.35. Given a truly distressed but gradually improving loss trend, this article presents the numbers plainly before laying out a careful, balanced view.
This Astec LifeSciences stock analysis walks through the narrowing loss trend across recent quarters and years, valuation considerations, shareholding pattern and the technical setup, using figures sourced from public filings.
Click Here – Get Free Investment Predictions
About Astec LifeSciences
Before deciding on Astec LifeSciences share price, it helps to understand the underlying business. Astec LifeSciences Ltd. manufactures agrochemical intermediates and active ingredients, serving the crop protection industry.
As an agrochemical intermediates manufacturer, Astec LifeSciences has worked through a truly difficult period of sustained losses, though the annual loss has narrowed meaningfully from FY24 to FY25, even as the company has not yet returned to profitability on either an annual or quarterly basis.
Astec LifeSciences Share Price Today: Key Levels
The table below summarises where Astec LifeSciences share price stands right now against its recent trading range and market value.
| Metric | Value |
|---|---|
| Astec LifeSciences CMP (NSE) | Rs 570.85 |
| Astec LifeSciences CMP (BSE) | Rs 569.15 |
| 52-Week High | Rs 941.75 |
| 52-Week Low | Rs 512.35 |
| Market Capitalisation | Approximately Rs 1,230 crore |
Astec LifeSciences share price is up today, though it remains well below its 52-week high, reflecting the market’s continued caution around the company’s ongoing losses.
Check the Univest Screener for Live Stock Data
Astec LifeSciences Financial Performance
The Astec LifeSciences share price trend is closely tied to how these numbers evolve each quarter. Astec LifeSciences reported Q1 FY27 (June 2026 quarter) revenue of Rs 84.29 crore, down 8 percent year on year from Rs 91.59 crore, with a net loss of Rs 18.71 crore, wider than the Rs 15.69 crore loss in the December 2025 quarter but narrower than the Rs 33.03 crore loss a year ago, showing a genuine, if uneven, improving trend over the past year.
For the full year FY25, the company reported revenue of Rs 453.22 crore, up 17.1 percent year on year, with the annual net loss narrowing to Rs 80.88 crore from Rs 134.71 crore in FY24, confirming a meaningful improvement at the annual level even though the business has not yet returned to profitability.
| Period | Revenue | Net Profit | Comment |
|---|---|---|---|
| Q1 FY27 (Jun 2026) | Rs 84.29 crore | Net loss Rs 18.71 crore | Narrower than the year-ago loss of Rs 33.03 crore |
| FY25 (full year) | Rs 453.22 crore | Net loss Rs 80.88 crore | Loss narrowed from Rs 134.71 crore in FY24 |
Valuation Check: Is Astec LifeSciences Share Price Expensive?
Any view on Astec LifeSciences share price should start from these valuation multiples. Given Astec LifeSciences’ continuing losses, with a negative trailing EPS of Rs -29.87, the price to earnings ratio is not meaningful here. Return on equity stands at -20.72 percent, reflecting the impact of the ongoing losses on the equity base.
The price to book ratio stands near 3.2 times. Debt to equity of 1.15 is elevated. Given the truly distressed but improving trend, investors should focus on the pace of loss narrowing in coming quarters rather than conventional valuation ratios.
Technical Signals: What the Chart Shows
Price action here often foreshadows the next move in Astec LifeSciences share price. Astec LifeSciences share price is up more than 3 percent today, positioned more than 39 percent below its 52-week high of Rs 941.75 and above its 52-week low of Rs 512.35, reflecting the market’s continued caution around the company’s sustained losses. A stock trading here after such a decline often reflects the market awaiting clearer evidence of a return to profitability before re-rating.
Trading volumes remain moderate, so investors should track Astec LifeSciences share price alongside continued confirmation of the narrowing loss trend in coming quarters, rather than reacting to any single day’s move at these technical levels.
Download the Univest iOS App or Univest Android App to track Astec LifeSciences’ live price and technical levels.
Shareholding Pattern
Shifts here can influence Astec LifeSciences share price more than headline news on some sessions. Astec LifeSciences is a promoter-led agrochemical intermediates manufacturer working through a truly distressed but gradually improving loss trend. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company’s latest exchange filing.
Why Investors Are Watching Astec LifeSciences
- Meaningfully narrowing annual losses: The FY25 annual loss narrowed to Rs 80.88 crore from Rs 134.71 crore in FY24, a genuine improvement in the underlying business trend.
- Continued FY25 revenue growth: Full-year FY25 revenue grew 17.1 percent year on year, showing underlying demand for the company’s agrochemical intermediates has not collapsed.
Risks and Factors to Watch
- Continuing losses with no return to profitability yet: Despite the narrowing trend, Astec LifeSciences has not yet returned to profitability on either an annual or quarterly basis, a genuine ongoing concern.
- Elevated leverage amid ongoing losses: A debt to equity ratio of 1.15 adds meaningful financial risk given the company’s continuing loss-making position.
- Agrochemical sector pricing pressure: As an agrochemical intermediates manufacturer, Astec LifeSciences faces exposure to competitive pricing pressure and raw material cost cycles that have contributed to its sustained losses.
- Uneven quarter-to-quarter improvement: The Q1 FY27 loss widened from the December 2025 quarter, showing the improving trend has not been perfectly linear.
Astec LifeSciences Share Price Target: What the Data Suggests
Until then, Astec LifeSciences share price remains best tracked through live, verified data rather than a single fixed number. Given Astec LifeSciences’ continuing losses, no reliable analyst price target framework applies to this stock at this time.
Investors considering this stock should track the Univest Screener for continued quarterly updates on the loss-narrowing trend, and should consult a SEBI-registered investment adviser given the truly distressed financial position involved.
Astec LifeSciences: Should You Buy, Hold, or Sell Right Now?
This is the core question behind Astec LifeSciences share price right now. The Astec LifeSciences buy or sell decision requires understanding a truly distressed but gradually improving situation.
The case for buying: Only investors with high risk tolerance who believe the narrowing loss trend will continue toward eventual profitability may consider a position, given the meaningful annual improvement already shown.
The case for holding: Existing shareholders who already accept this risk profile may choose to continue monitoring for continued loss narrowing.
The case for avoiding: Most investors, particularly those seeking companies with a clear path to profitability, would reasonably prefer to wait for the company to actually return to profit before considering this stock.
Given the continuing losses here, consult a SEBI-registered investment adviser before proceeding.
Conclusion
Astec LifeSciences share price reflects an agrochemical intermediates manufacturer working through a truly distressed period, with losses narrowing meaningfully at the annual level even as the company has not yet returned to profitability. This article is for informational purposes and not a personalised investment recommendation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Q1. Is Astec LifeSciences a good stock to buy right now?
Ans. Astec LifeSciences’ losses have narrowed meaningfully, from Rs 134.71 crore in FY24 to Rs 80.88 crore in FY25, but the company has not yet returned to profitability. This is a truly distressed but improving situation suitable only for investors with higher risk tolerance.
Q2. Why did Astec LifeSciences’ share price rise today?
Ans. Astec LifeSciences share price rose more than 3 percent today, though no specific catalyst was clearly identified in available disclosures at the time of writing.
Q3. What is the Astec LifeSciences share price today?
Ans. Astec LifeSciences share price is trading around Rs 571 on the NSE. The stock’s 52-week high is Rs 941.75 and its 52-week low is Rs 512.35.
Q4. What is the Astec LifeSciences share price target?
Ans. Given Astec LifeSciences’ continuing losses, no reliable analyst price target framework applies to this stock at this time.
Q5. Is Astec LifeSciences profitable?
Ans. No, Astec LifeSciences posted a net loss of Rs 18.71 crore in Q1 FY27, though this was narrower than the year-ago loss of Rs 33.03 crore, part of a broader narrowing trend since FY24.
Q6. What does Astec LifeSciences manufacture?
Ans. Astec LifeSciences manufactures agrochemical intermediates and active ingredients, serving the crop protection industry.